Tesla sales are diving in Germany and across Europe too
Tesla sales have careened lower in Germany in January, as sales of the electric vehicle company headed by Elon Musk tumble across Europe. View Source…
Category: MarketWatch
Pay attention to what junk bonds are saying about the value of Treasury bonds
High-yield bond holders aren’t asking for much of a premium above ultra-safe U.S. Treasurys. Time to own quality. View Source MarketWatch.com – Top Stories February…
Uber’s stock falls in the face of its ‘strongest quarter ever.’ Here’s why.
The ride-hailing company faces stiff pressure from the strong U.S. dollar, which is weighing on its forecast for the current quarter. View Source MarketWatch.com –…
Harley-Davidson shares slip after Q4 loss amid ‘cyclical headwinds for discretionary products’
View Source MarketWatch.com – MarketPulse February 5, 2025 5:15 am
Vanguard made it cheaper to invest in ETFs. What the fee war means for investors.
The world’s second-largest asset manager has slashed the cost of fund investing, in a record move that is expected to save investors more than $350…
DeepSeek and tariffs have roiled the market. History says deeper pullbacks are coming, this strategist says.
Don’t be tempted to buy on these headline-driven stock-market dips, bigger opportunities are coming, says Truist’s Keith Lerner. View Source MarketWatch.com – Top Stories February…
Disney’s stock rise toward a 2-month high after earnings beat, affirmed outlook
View Source MarketWatch.com – MarketPulse February 5, 2025 4:54 am
European stocks are beating the U.S. so far this year. Is American exceptionalism dead?
European stocks are off to a strong start in 2025. Some financial luminaries, most notably BlackRock Chief Executive Larry Fink, have recently said the time…
Nvidia, Caterpillar and other winners and losers from DeepSeek’s emergence, according to JPMorgan
Nvidia — whose market cap dropped by $600 billion in a single day on the emergence of the Chinese AI chatbot DeepSeek — is actually…
Novo Nordisk sales beat estimates, but the story wasn’t Ozempic
Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. View…